Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

GlaxoSmithKline launches satellite R&D teams in search of new products
Fierce Pharma
Wednesday, November 27, 2013 - 11:55am
tags:
GSK, R&D
CVS Caremark to buy Apria's infusion business for $2.1 billion
Reuters
Wednesday, November 27, 2013 - 11:55am
tags:
CVS Caremark, Apria, infusion, devices, M&A
How Will GlaxoSmithKline Plc Fare In 2014?
Motley Fool
Wednesday, November 27, 2013 - 11:53am
tags:
GSK
Keep An Eye On GW, Johnson & Johnson, Durata, and Merck Today
Motley Fool
Wednesday, November 27, 2013 - 9:58am
tags:
JNJ, Durata Therapeutics, Merck, GW Pharma, Olysio, Savitex, Noxafil, Dalvance
3 Biotech Stocks That Soared on Tuesday
Wall St Cheat Sheet
Wednesday, November 27, 2013 - 9:56am
tags:
Clovis Oncology, Echo Therapeutics, Merrimack Pharmaceuticals
BTG wins FDA OK for varicose vein treatment, projects $500M peak
Fierce Biotech
Wednesday, November 27, 2013 - 8:59am
tags:
varicose veins, BTG, FDA, Varithena, devices
CSL’s potential new treatment for heart disease could boost profits further
Motley Fool
Wednesday, November 27, 2013 - 8:53am
tags:
CSL
You Call That Efficacy? FDA Warns Amgen For Aranesp Promotion
Pharmalot
Wednesday, November 27, 2013 - 8:51am
tags:
FDA, Amgen, Aranesp
FDA reviewing if weight limits effect of "morning after" pill
Reuters
Wednesday, November 27, 2013 - 8:44am
tags:
FDA, morning-after pill, Norlevo
Teva announces additional regulatory exclusivity for TREANDA
The Fly on the Wall
Wednesday, November 27, 2013 - 8:41am
tags:
Teva, Treanda, rituximab, indolent non-Hodgkin's lymphoma
2014 FDA Drug Approval Decision Calendar
TheStreet.com
Wednesday, November 27, 2013 - 8:39am
tags:
FDA, drug approvals, GSK, Gilead, Theravance, Auxilium, Amarin, Bristol-Myers Squibb, Biogen Idec, Pozen, Vanda, Chelsea Therapeutics, pSivida, Alimera, United Therapeutics, Biomarin, JNJ, Pharmacyclics, Celgene, MannKind, Santarus, AstraZeneca, Durata Therapeutics, Eli Lilly, Omeros, BioDelivery Sciences, Anacor, Keryx, Cubist Pharmaceuticals, Nektar
Four Biotech 'Surprise' Stocks for 2014
TheStreet.com
Wednesday, November 27, 2013 - 8:34am
tags:
Seattle Genetics, Adcetris, Cubist Pharmaceuticals, Cempra, Eylea, Regeneron, Pharmacyclics, Imbruvica, Gilead, sofosbuvir
Celsion Prepares For Phase III Trial Redux
Seeking Alpha
Wednesday, November 27, 2013 - 8:32am
tags:
Celsion, ThermoDox
Celldex, ImmunoCellular Fall And Rise On Hype And Hope
Seeking Alpha
Wednesday, November 27, 2013 - 8:31am
tags:
ImmunoCellular Therapeutics, Celldex, rindopepimut, glioblastoma, ICT-107
AstraZeneca: A Positive Future Awaits This Company
Seeking Alpha
Tuesday, November 26, 2013 - 4:48pm
tags:
AstraZeneca, Bristol-Myers Squibb, Xigduo, diabetes, Dapagliflozin
3 Can't-Miss FDA Actions Coming in December
Motley Fool
Tuesday, November 26, 2013 - 4:42pm
tags:
FDA, Gilead Sciences, sofosbuvir, Forxiga, AstraZeneca, Bristol-Myers Squibb, GSK, Anoro Ellipta, Theravance
Ventrus Bio Poised For Run-Up Into Second Round Of Phase III Results
Seeking Alpha
Tuesday, November 26, 2013 - 4:41pm
tags:
Ventrus Biosciences, VEN 307
Biogen's Tecfidera Time-Out Pays Off
Motley Fool
Tuesday, November 26, 2013 - 4:38pm
tags:
Tecfidera, Biogen Idec, MS, multiple sclerosis
New Hepatitis C Drug Success Should Drive Gilead Sciences In 2014
Seeking Alpha
Tuesday, November 26, 2013 - 4:37pm
tags:
hepatitis C, Gilead Sciences, sofosbuvir
What's Behind Galena Biopharma's Recent Run?
Motley Fool
Tuesday, November 26, 2013 - 4:34pm
tags:
Galena Biopharma, Abstral, NeuVax, INSYS Therapeutics

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.